Bio-Rad acquires GnuBIO and DNA sequencing technology

April 21, 2014

Bio-Rad Laboratories, Inc., manufacturer and distributor of life science research and clinical diagnostic products, has purchased GnuBIO, Inc. Based in Cambridge, MA, GnuBIO is developing a fast and fully integrated droplet-based DNA sequencing technology that incorporates all the functions of DNA sequencing into a single, integrated workflow for medical diagnostics as well as research markets. According to company representatives, this sequencing technology does not require separate workflows for target selection, DNA amplification, DNA sequencing and analysis, but rather will integrate the entire workflow into a single, low-cost solution that produces results within hours.

“We are pleased to have GnuBIO join Bio-Rad,” says Norman Schwartz, Bio-Rad President and CEO. “We believe GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage Bio-Rad's leadership role in the area of droplet digital PCR.” Learn more about GnuBIO.

Read more

ID 310202522 © Oleksandra Tsvid | Dreamstime.com
dreamstime_xxl_310202522_2
ID 292063206 © Artem Evdokimov | Dreamstime.com
dreamstime_xxl_292063206
ID 186157453 © Noipornpan | Dreamstime.com
dreamstime_xxl_186157453
By MVProductions on Adobe Stock
adobestock_1186979838
ID 5801699 © Aurinko | Dreamstime.com
dreamstime_xxl_5801699